Ypozane Tablets 7.5mg (pack of 7)

Ypozane tablets for dogs are a highly effective treatment for benign prostatic hypertrophy (BPH) in male canines. In dogs with BPH associated with prostatitis, Ypozane can be administered concurrently with antimicrobials.

Each Ypozane tablet contains the active ingredient osaterone acetate which is a steroid anti-androgen. They are white, round 9mm tablets and come in blister packs of 7 tablets.

How To Buy Ypozane Tablets

Ypozane dog tablets are a prescription-only medication. This means that before you complete your purchase, you are required to upload a prescription through our online portal.

After our team has confirmed you've ordered the right medication for your dog, we can send out your order. It's a simple process that means you can buy Ypozane dog medication online instead of going to your vet every month.

How To Use Ypozane Tablets

Yzopane tablets are administered orally either directly into your dog's mouth, or via pet food.

Used for the treatment of benign prostatic hypertrophy, the following average doses are advised. However, the actual dose used should be determined by the severity of the signs and the length of time for which they have been present.

• One single 1.875mg Ypozane tablet for dogs bodyweight of 3 to 7.5kg
• One single 3.75mg Ypozane tablet for dogs bodyweight of 7.5kg to 15kg
• One single 7.5mg Ypozane tablet for dogs bodyweight of 15kg to 30kg
• One single 15mg Ypozane tablet for dogs bodyweight of 30 kg to 60kg

A clinical response to treatment using Ypozane tablets is usually observed within two weeks, however this can persist for at least 5 months after treatment.

For more information on Ypozane tablets for dogs, and how to use them, please see the product label or contact your veterinarian.

Special Precautions

For use in animals only. Dogs under stress should be continuously monitored if prescribed Ypozane tablets.

Ypozane should be administered using caution with dogs with a history of liver disease.

A very common adverse reaction includes an increase in appetite. Other notable common adverse reactions include an increase in social activity, Less common reactions include vomiting and/or diarrhoea, lethargy and mammary gland hyperplasia. A transient reduction in plasma cortisol occurs in most treated dogs.

Target species

Dogs (male)

Indications for use

Treatment of benign prostatic hypertrophy (BPH) in male dogs.

Contra-indications

None

Special warnings for each target species

In dogs with BPH associated with prostatitis, the product can be administered concurrently with antimicrobials

Special precautions for use

Special precautions for use in animals

A transient reduction of plasma cortisol concentration may occur; this may continue for several weeks after administration. Appropriate monitoring should be implemented in dogs under stress (e.g. postoperative) or those with hypoadrenocorticism. The response to an ACTH stimulation test may also be suppressed for several weeks after administration of osaterone.

Use with caution in dogs with a history of liver disease, as safety of use of the product in these dogs has not been thoroughly investigated, and as treatment of some dogs with liver disease has resulted in reversible elevation of ALT and ALP in clinical trials.

Special precautions to be taken by the person administering the veterinary medicinal product to animals Wash hands after administration.

In the case of accidental ingestion by a person, seek medical advice immediately and show the package leaflet or the label to the physician. A single oral dose of 40 mg osaterone acetate in human males was followed by a sporadic decrease in FSH, LH and testosterone, reversible after 16 days. There was no clinical effect. In female laboratory animals, osaterone acetate caused serious adverse effects on reproductive functions. Therefore, women of child-bearing age should avoid contact with, or wear disposable gloves, when administering the product.

Adverse reactions

A transient increase in appetite occurs very commonly.

Transient behavioural changes such as increased or decreased activity, or more sociable behaviour, arecommon. Other adverse reactions, including transient vomiting and/or diarrhoea, polyuria/polydipsia, lethargy or feminisation syndrome including mammary gland hyperplasia occur uncommonly.

A transient reduction in plasma cortisol occurs in most treated animals.

In clinical trials, treatment with the veterinary medicinal product was not discontinued and all dogs recovered without any specific therapy.

Use during pregnancy, lactation or lay

Not applicable

Interactions

None known